267 related articles for article (PubMed ID: 19046817)
1. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review.
Pentheroudakis G; Greco FA; Pavlidis N
Cancer Treat Rev; 2009 May; 35(3):221-7. PubMed ID: 19046817
[TBL] [Abstract][Full Text] [Related]
2. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.
Hainsworth JD; Rubin MS; Spigel DR; Boccia RV; Raby S; Quinn R; Greco FA
J Clin Oncol; 2013 Jan; 31(2):217-23. PubMed ID: 23032625
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site.
Kodaira M; Yonemori K; Shimoi T; Yoshida A; Yoshida M; Kitano A; Shimomura A; Yunokawa M; Shimizu C; Takiguchi Y; Fujiwara Y; Tamura K
BMC Cancer; 2018 Feb; 18(1):176. PubMed ID: 29433539
[TBL] [Abstract][Full Text] [Related]
4. A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile.
Hainsworth JD; Schnabel CA; Erlander MG; Haines DW; Greco FA
Clin Colorectal Cancer; 2012 Jun; 11(2):112-8. PubMed ID: 22000811
[TBL] [Abstract][Full Text] [Related]
5. Switching benchmarks in cancer of unknown primary: from autopsy to microarray.
Pentheroudakis G; Golfinopoulos V; Pavlidis N
Eur J Cancer; 2007 Sep; 43(14):2026-36. PubMed ID: 17698346
[TBL] [Abstract][Full Text] [Related]
6. Optimal therapeutic management of patients with distinct clinicopathological cancer of unknown primary subsets.
Pavlidis N
Ann Oncol; 2012 Sep; 23 Suppl 10():x282-5. PubMed ID: 22987978
[TBL] [Abstract][Full Text] [Related]
7. Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer.
Riihimäki M; Thomsen H; Hemminki A; Sundquist K; Hemminki K
BMC Cancer; 2013 Jan; 13():36. PubMed ID: 23356713
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study.
Pentheroudakis G; Briasoulis E; Kalofonos HP; Fountzilas G; Economopoulos T; Samelis G; Koutras A; Karina M; Xiros N; Samantas E; Bamias A; Pavlidis N;
Acta Oncol; 2008; 47(6):1148-55. PubMed ID: 18607872
[TBL] [Abstract][Full Text] [Related]
9. A systematic overview of chemotherapy effects in breast cancer.
Bergh J; Jönsson PE; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):253-81. PubMed ID: 11441936
[TBL] [Abstract][Full Text] [Related]
10. Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial.
Hayashi H; Takiguchi Y; Minami H; Akiyoshi K; Segawa Y; Ueda H; Iwamoto Y; Kondoh C; Matsumoto K; Takahashi S; Yasui H; Sawa T; Onozawa Y; Chiba Y; Togashi Y; Fujita Y; Sakai K; Tomida S; Nishio K; Nakagawa K
JAMA Oncol; 2020 Dec; 6(12):1931-1938. PubMed ID: 33057591
[TBL] [Abstract][Full Text] [Related]
11. Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site.
Hayashi H; Kurata T; Takiguchi Y; Arai M; Takeda K; Akiyoshi K; Matsumoto K; Onoe T; Mukai H; Matsubara N; Minami H; Toyoda M; Onozawa Y; Ono A; Fujita Y; Sakai K; Koh Y; Takeuchi A; Ohashi Y; Nishio K; Nakagawa K
J Clin Oncol; 2019 Mar; 37(7):570-579. PubMed ID: 30653423
[TBL] [Abstract][Full Text] [Related]
12. Progress in refining the clinical management of cancer of unknown primary in the molecular era.
Rassy E; Pavlidis N
Nat Rev Clin Oncol; 2020 Sep; 17(9):541-554. PubMed ID: 32350398
[TBL] [Abstract][Full Text] [Related]
13. Overview of various techniques/platforms with critical evaluation of each.
Agwa E; Ma PC
Curr Treat Options Oncol; 2013 Dec; 14(4):623-33. PubMed ID: 24243164
[TBL] [Abstract][Full Text] [Related]
14. Capecitabine and oxaliplatin as second-line treatment in patients with carcinoma of unknown primary site.
Møller AK; Pedersen KD; Abildgaard J; Petersen BL; Daugaard G
Acta Oncol; 2010 May; 49(4):431-5. PubMed ID: 20235750
[TBL] [Abstract][Full Text] [Related]
15. Cancer of unknown primary site: review of consecutive cases at the National Cancer Center Hospital of Japan.
Yakushiji S; Ando M; Yonemori K; Kohno T; Shimizu C; Katsumata N; Fujiwara Y
Int J Clin Oncol; 2006 Dec; 11(6):421-5. PubMed ID: 17180509
[TBL] [Abstract][Full Text] [Related]
16. p16 expression in carcinoma of unknown primary: diagnostic indicator and prognostic marker.
Vent J; Haidle B; Wedemeyer I; Huebbers C; Siefer O; Semrau R; Preuss SF; Klussmann J
Head Neck; 2013 Nov; 35(11):1521-6. PubMed ID: 23345170
[TBL] [Abstract][Full Text] [Related]
17. Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature.
Lazaridis G; Pentheroudakis G; Fountzilas G; Pavlidis N
Cancer Treat Rev; 2008 Dec; 34(8):693-700. PubMed ID: 18584969
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and therapeutic management of cancer of an unknown primary.
Pavlidis N; Briasoulis E; Hainsworth J; Greco FA
Eur J Cancer; 2003 Sep; 39(14):1990-2005. PubMed ID: 12957453
[TBL] [Abstract][Full Text] [Related]
19. Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature.
Overby A; Duval L; Ladekarl M; Laursen BE; Donskov F
Clin Genitourin Cancer; 2019 Feb; 17(1):e32-e37. PubMed ID: 30268423
[TBL] [Abstract][Full Text] [Related]
20. Clinical and immune profiling for cancer of unknown primary site.
Haratani K; Hayashi H; Takahama T; Nakamura Y; Tomida S; Yoshida T; Chiba Y; Sawada T; Sakai K; Fujita Y; Togashi Y; Tanizaki J; Kawakami H; Ito A; Nishio K; Nakagawa K
J Immunother Cancer; 2019 Sep; 7(1):251. PubMed ID: 31519206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]